Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2018-10-25
• Target enrollment: 0
• Participant gender: All

Summary

To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aerie Pharmaceuticals
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

1. Must be 18 years or older

2. Be of Japanese ethnicity within the 2nd generation defined as (a) 1st generation born in Japan, immigrated to US and (b) 2nd generation - parents are 1st generation and patient was born in US as an American citizen

3. Diagnosis of open-angle glaucoma or ocular hypertension in both eyes

4. Medicated intraocular pressure >/= 15 mmHg and < 30 mmHg in both eyes at screening

5. OAG eyes - unmedicated IOP >/= 15 mmHg and < 35 mmHg at 2 qualification visits at 08:00, 10:00 and 16:00

6. OHT eyes - unmedicated IOP >/= 22 mmHg and < 35mmHg at 08:00, 10:00 and 16:00

7. Best corrected visual acuity + 1.0 logMAR or better by ETDRS in each eye

8. Able to give signed informed consent and follow instructions

Exclusion Criteria:

1. Clinically significant ocular disease

2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma or narrow angles

3. Intraocular pressure >/=35 mmHg in either eye

4. Ocular hyperemia score of moderate (+2) at qualification visit #2

5. Previous glaucoma intraocular surgery

6. Refractive surgery in either eye

7. Ocular injury within 6 months prior to screening or ocular surgery or non-refractive laser treatment within 3 months prior to screening

8. Recent or current ocular infection or inflammation in either eye

9. Use of ocular medication in either eye of any kind within 30 days of screening and throughout the study

10. Mean central corneal thickness > 620 µm in either eye

11. Any abnormality preventing reliable applanation tonometry of either eye

12. Known hypersensitivity to benzalkonium chloride or excipients of netarsudil ophthalmic solution

13. Clinically significant abnormalities in screening lab tests

14. Clinically significant systemic disease that might interfere with the study

15. Participated in any investigational study within 30 days prior to screening

16. Systemic medication that could have a substantial effect on IOP within 30 days prior to screening or anticipated during the study

17. Women of child-bearing potential who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control